Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Genethon SA - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Genethon SA - Product Pipeline Review - 2016', provides an overview of the Genethon SA's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Genethon SA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Genethon SA - The report provides overview of Genethon SA including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Genethon SA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Genethon SA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Genethon SA's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Genethon SA - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Genethon SA's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Genethon SA Snapshot 6 Genethon SA Overview 6 Key Facts 6 Genethon SA - Research and Development Overview 7 Key Therapeutic Areas 7 Genethon SA - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 Pipeline Products - Partnered Products 12 Partnered Products/Combination Treatment Modalities 13 Genethon SA - Pipeline Products Glance 14 Genethon SA - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Genethon SA - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Genethon SA - Drug Profiles 17 Cell Therapy to Activate FANC-A for Fanconi Anemia - Drug Profile 17 Product Description 17 Mechanism Of Action 17 R&D Progress 17 CPK-850 - Drug Profile 18 Product Description 18 Mechanism Of Action 18 R&D Progress 18 G-1XCGD - Drug Profile 19 Product Description 19 Mechanism Of Action 19 R&D Progress 19 Gene Therapy for Duchenne Muscular Dystrophy - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 Gene Therapy for Sickle Cell Disease - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 Gene Therapy to Activate Dysferlin for Dysferlinopathies - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 Gene Therapy to Activate Factor IX for Hemophilia B - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Gene Therapy to Activate Gamma-Sarcoglycan for Gamma Sarcoglycanopathy - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 Gene Therapy to Activate SGCA for Alpha-Sarcoglycanopathy - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Gene Therapy to Activate SMN1 for Spinal Muscular Atrophy - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Gene Therapy to Activate UGT1A1 for Crigler-Najjar Syndrome - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Stem Cell Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Stem Cell Therapy to Activate WASP for Wiskott-Aldrich Syndrome - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Genethon SA - Pipeline Analysis 35 Genethon SA - Pipeline Products by Target 35 Genethon SA - Pipeline Products by Route of Administration 36 Genethon SA - Pipeline Products by Molecule Type 37 Genethon SA - Pipeline Products by Mechanism of Action 38 Genethon SA - Dormant Projects 39 Genethon SA - Locations And Subsidiaries 40 Head Office 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables
Genethon SA, Key Facts 6 Genethon SA - Pipeline by Indication, 2016 9 Genethon SA - Pipeline by Stage of Development, 2016 10 Genethon SA - Monotherapy Products in Pipeline, 2016 11 Genethon SA - Partnered Products in Pipeline, 2016 12 Genethon SA - Partnered Products/ Combination Treatment Modalities, 2016 13 Genethon SA - Phase II, 2016 14 Genethon SA - Preclinical, 2016 15 Genethon SA - Discovery, 2016 16 Genethon SA - Pipeline by Target, 2016 35 Genethon SA - Pipeline by Route of Administration, 2016 36 Genethon SA - Pipeline by Molecule Type, 2016 37 Genethon SA - Pipeline Products by Mechanism of Action, 2016 38 Genethon SA - Dormant Developmental Projects,2016 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
